BioCentury
ARTICLE | Clinical News

MM-310: Ph I started

March 30, 2017 12:58 AM UTC

Merrimack began an open-label, U.S. Phase I trial to evaluate IV MM-310 on day 1 of each 21-day cycle. A dose-escalation part will determine the MTD of MM-310 alone in up to 34 patients. The trial wil...

BCIQ Company Profiles

Merrimack Pharmaceuticals Inc.

BCIQ Target Profiles

EPH receptor A2 (EPHA2)